KLRK1 and Crohn disease: Additionally, (R)-ketamine might be a potential therapeutic drug for inflammation-related diseases, as a clinical trial of anti-NKG2D antibody is underway for inflammation-related diseases such as Crohn’s disease and rheumatoid arthritis [21, 48].